Comparative Effects of Repeated Ketamine Infusion Versus Intranasal Esketamine in Patients With Treatment-Resistant Depression
The Journal of Clinical Psychiatry · 2025
DOI: 10.4088/jcp.25m15789 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift The Journal of Clinical Psychiatry, 2025. Verfasst von Robert Meisner und 8 weiteren Autor:innen. Beteiligte Einrichtung: Psychiatric Neurotherapeutics Program, McLean Hospital, Belmont, Massachusetts. Hauptthemen laut MEDLINE: Ketamine, Depressive Disorder, Treatment-Resistant, Antidepressive Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref).
Themen: Depression
Abstract (Originalsprache)
Objective
Both intravenous (IV) racemic ketamine and intranasal (IN) esketamine have emerged as rapid-acting antidepressants for treatment-resistant depression (TRD) and are increasingly used in clinical settings. Relatively few studies, however, have compared these interventions in larger, naturalistic cohorts. This study was conducted to assess the comparative efficacy and rapidity of response observed with repeated IV ketamine versus IN esketamine in a psychiatric neurotherapeutics specialty service. Through retrospective chart review, we conducted what is, to the best of our knowledge, among the larger such comparisons to date.
Methods
Data from 153 patients with severe TRD were reviewed (111 patients received IV ketamine and 42 patients received IN esketamine). In accordance with consensus criteria for TRD and validated objective criteria for illness severity, included patients failed a minimum of 2 adequate antidepressant treatment trials and demonstrated a preketamine treatment score of 16 or higher on the 16-item Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR16). Severity of depression was subsequently reassessed with the QIDS-SR16 prior to each ketamine and esketamine administration. A 2-way analysis of variance was used to compare changes in QIDS-SR16 scores between the IV ketamine and IN esketamine treatment groups.
Results
With equivalent depression severity measured by QIDS-SR16 at pretreatment baseline, the IV ketamine treatment group showed significantly greater decreases in QIDS-SR16 scores compared to the IN esketamine group, as measured immediately before each treatment from the third to the eighth session (all P values < .05). Patients who received IV ketamine infusions demonstrated a 49.22% reduction in QIDS-SR16 scores by the eighth treatment, while patients who received IN esketamine over the same induction period showed a 39.55% reduction. As expected, both IV ketamine and IN esketamine treatments resulted in significant decreases in QIDS-SR16 scores. In the IV ketamine group, the decrease in QIDS-SR16 scores reached significance after 1 treatment, while in the IN esketamine treatment group, the decrease in QIDS-SR16 scores reached significance after the second treatment.
Conclusion
In this naturalistic sample of patients with similarly severe TRD treated in a ketamine subspecialty service over a 4-5-week induction period, treatment with IV racemic ketamine was associated with a more rapid response and greater overall efficacy than treatment with IN esketamine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Psychiatric Neurotherapeutics Program, McLean Hospital, Belmont, Massachusetts.
- Acute Psychiatric Service, Massachusetts General Hospital, Boston, Massachusetts.
- Department of Psychiatry, Harvard Medical School, Boston, Massachusetts.
- Corresponding Author: Shuang Li, PhD, MD, Psychiatric Neurotherapeutics Program, McLean Hospital, 115 Mill St, Belmont, MA 02478 (shuang.li@mgh.harvard.edu). Meisner and Li contributed equally to this work.
Zitieren
APA
Meisner, R., Li, S., Boyle, B., Valdivia, V., Sedgewick, A., Dai, D., Miller, C., Bolton, P., & Seiner, S. (2025). Comparative Effects of Repeated Ketamine Infusion Versus Intranasal Esketamine in Patients With Treatment-Resistant Depression. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.25m15789
Vancouver
Meisner R, Li S, Boyle B, Valdivia V, Sedgewick A, Dai D, et al. Comparative Effects of Repeated Ketamine Infusion Versus Intranasal Esketamine in Patients With Treatment-Resistant Depression. The Journal of Clinical Psychiatry. 2025. doi:10.4088/jcp.25m15789
BibTeX
@article{Meisner2025,
author = {Meisner, Robert and Li, Shuang and Boyle, Brian and Valdivia, Violeta and Sedgewick, Amanda and Dai, Danika and Miller, Courtney and Bolton, Paula and Seiner, Steve},
title = {Comparative Effects of Repeated Ketamine Infusion Versus Intranasal Esketamine in Patients With Treatment-Resistant Depression},
journal = {The Journal of Clinical Psychiatry},
year = {2025},
doi = {10.4088/jcp.25m15789}
}
EUVIMED